Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections

被引：8

作者：

Watkins, Richard R. ^{[1
,4
]}

Bonomo, Robert A. ^{[2
,3
]}

机构：

[1] Northeast Ohio Med Univ, Dept Med, Div Infect Dis, Rootstown, OH USA

[2] VA Northeast Ohio Healthcare Syst, Res Serv, Cleveland, OH USA

[3] Case Western Reserve Univ, Cleveland VA Med Ctr Antimicrobial Resistance & Ep, Cleveland, OH USA

[4] Northeast Ohio Med Univ, Dept Med, 4209 St,OH 44, Rootstown, OH 44272 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2023年 / 76卷

关键词：

antimicrobial resistance; carbapenem-resistant Acinetobacter baumannii; sulbactam-durlobactam; BETA-LACTAM ANTIBIOTICS;

D O I：

10.1093/cid/ciad093

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Antimicrobial resistance in gram-negative pathogens, such as Acinetobacter baumannii, is a serious threat to human health. Sulbactam-durlobactam, a unique beta-lactam and a beta-lactamase inhibitor combination, is a novel agent targeted against carbapenem-resistant A. baumannii. This supplement provides a summary of the development of SUL-DUR, discussing its unique features and role in treating infections caused by CRAB pathogens.

引用

页码：S163 / S165

页数：3

共 50 条

[1] Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections
August, Benjamin
Matlob, Andrew
Kale-Pradhan, Pramodini B.
ANNALS OF PHARMACOTHERAPY, 2024, 58 (07) : 735 - 741
[2] The role of sulbactam-durlobactam in treating carbapenem-resistant Acinetobacter infections
Bassetti, Matteo
Giacobbe, Daniele Roberto
Castaldo, Nadia
Vena, Antonio
CURRENT OPINION IN INFECTIOUS DISEASES, 2024, 37 (06) : 547 - 553
[3] Sulbactam-Durlobactam for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections
Marzella, Nino
Kish, Troy
Costinas, Carmen-Sarah
Dima, Lorena
Nguyen, Timothy
AMERICAN JOURNAL OF THERAPEUTICS, 2025, 32 (02) : e151 - e158
[4] Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii
Karruli, Arta
Migliaccio, Antonella
Pournaras, Spyros
Durante-Mangoni, Emanuele
Zarrilli, Raffaele
ANTIBIOTICS-BASEL, 2023, 12 (12):
[5] Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis With Sulbactam-Durlobactam
Tamma, Pranita D.
Immel, Shanan
Karaba, Sara M.
Soto, Caitlin L.
Conzemius, Rick
Gisriel, Emily
Tekle, Tsigereda
Stambaugh, Haley
Johnson, Emily
Tornheim, Jeffrey A.
Simner, Patricia J.
CLINICAL INFECTIOUS DISEASES, 2024, 79 (04) : 819 - 825
[6] In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance
Findlay, Jacqueline
Poirel, Laurent
Bouvier, Maxime
Nordmann, Patrice
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2022, 30 : 445 - 450
[7] Sulbactam-durlobactam: A novel β-lactam-β-lactamase inhibitor combination targeting carbapenem-resistant Acinetobacter baumannii infections
El-Ghali, Amer
Coyne, Ashlan Kunz J.
Caniff, Kaylee
Bleick, Callan
Rybak, Michael J.
PHARMACOTHERAPY, 2023, 43 (06): : 502 - 513
[8] Sulbactam and Durlobactam Combination as a Newer Antibiotic for Carbapenem-Resistant Acinetobacter baumannii Infections
Nyamagoud, Sanatkumar Bharamu
Swamy, Agadi Hiremath Viswanatha
Abhishek, B. J.
Varghese, Leena Elizabeth
Bhoomika, S. K.
INTERNATIONAL JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2024, 14 (02) : 289 - 298
[9] Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece
Petropoulou, Dimitra
Siopi, Maria
Vourli, Sophia
Pournaras, Spyros
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 11
[10] COST-EFFECTIVENESS OF SULBACTAM-DURLOBACTAM COMPARED TO COLISTIN IN TREATING CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII INFECTIONS IN CRITICAL CARE SETTING IN THE UNITED STATES: A DECISION ANALYSIS
Ologunowa, A.
Caffrey, A. R.
Kogut, S.
VALUE IN HEALTH, 2024, 27 (06) : S133 - S133

← 1 2 3 4 5 →